Zymeworks Inc logo

ZYME - Zymeworks Inc Share Price

$36.16 -1.0  -2.7%

Last Trade - 22/05/20

Mid Cap
Market Cap £1.35bn
Enterprise Value £952.7m
Revenue £21.3m
Position in Universe 1843rd / 6359
Unlock ZYME Revenue
Relative Strength (%)
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Margin of Safety
Qualifying GuruScreens
Financial Summary
FINANCIAL BRIEF: : For the three months ended 31 March 2020, Zymeworks Inc revenues decreased 31% to $8.3M. Net loss increased from $13.6M to $31.1M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Research and development increase from $17.5M to $36.5M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$0.43 to -$0.64.
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History


ZYME Revenue Unlock ZYME Revenue

Net Income

ZYME Net Income Unlock ZYME Revenue

Normalised EPS

ZYME Normalised EPS Unlock ZYME Revenue

PE Ratio Range

ZYME PE Ratio Range Unlock ZYME Revenue

Dividend Yield Range

ZYME Dividend Yield Range Unlock ZYME Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
ZYME EPS Forecasts Unlock ZYME Revenue
Profile Summary

Zymeworks Inc is a Canada-based biopharmaceutical company. The Company specializes in the discovery, development and commercialization of next-generation multifunctional biotherapeutics, initially focused on the treatment of cancer. The Company operates through a number of platforms, including Azymetric platform, which is developed for the development of IgG-like, novel bispecific antibodies for the targeting of synergistic drug targets; Albucore platform, which is developed as a flexible and alternative platform to antibodies where it is advantageous for multi-valent therapeutic to target multiple disease targets; Effect, which comprises a library of Fc modifications that can selectively modulate the activity of recruited immune cells, and the ZymeLink Conjugation platform, which is a suite of novel protein site-specific conjugation technologies and customizable cleavable and non-cleavable linkers that is compatible with a variety of small molecule therapeutics.

Last Annual December 31st, 2019
Last Interim March 31st, 2020
Incorporated May 2, 2017
Public Since April 28, 2017
No. of Shareholders: 31
No. of Employees: 267
Sector Healthcare
Industry Biotechnology & Medical Research
Exchange New York Stock Exchange
Shares in Issue 45,533,201
Free Float (0.0%)
Eligible for
ZYME Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for ZYME
Upcoming Events for ZYME
Thursday 4th June, 2020
Zymeworks Inc at Jefferies Healthcare Conference (Virtual)
Monday 3rd August, 2020 Estimate
Q2 2020 Zymeworks Inc Earnings Release
Thursday 5th November, 2020 Estimate
Q3 2020 Zymeworks Inc Earnings Release
Similar to ZYME
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.